Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lars Masanneck

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Neurological Research and Practice|December 29, 2022
Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019Marc Pawlitzki, Laura Acar, Lars Masanneck, et al.
Journal of Central Nervous System Disease|February 16, 2026
Case-Based Lessons on Remote Patient Monitoring in Neurology Using Consumer-Grade WearablesPaula Z Epping, Ramona Hagler, Noah M Werner, et al.
Neurological Research and Practice|June 13, 2026
Rethinking EDSS-based ambulation assessment in multiple sclerosis using continuous variable monitoringNoah M Werner, Melanie Schuette, Ramona Hagler, et al.
International Journal of Molecular Sciences|September 28, 2021
Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple SclerosisAnna Vogelsang, Susann Eichler, Niklas Huntemann, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromesTobias Ruck, Niklas Huntemann, Menekse Öztürk, et al.
Journal of Neurology|July 10, 2026
From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosisHernan Inojosa, Lars Masanneck, Katja Akgün, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapiesLars Masanneck, Leoni Rolfes, Liesa Regner-Nelke, et al.
PLOS Digital Health|July 1, 2026
Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspectiveHernan Inojosa, Lars Masanneck, Isabel Voigt, et al.
Therapeutic Advances in Neurological Disorders|March 26, 2026
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysisPatricia Kirschner, Franz F Konen, Franziska Axhausen, et al.
Annals of Clinical and Translational Neurology|July 10, 2025
Digital Activity Markers in Chronic Inflammatory Demyelinating PolyneuropathyLars Masanneck, Jan Voth, Noëmi Gmahl, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Neurological Research and Practice|December 29, 2022
Myositis in Germany: epidemiological insights over 15 years from 2005 to 2019Marc Pawlitzki, Laura Acar, Lars Masanneck, et al.
Journal of Central Nervous System Disease|February 16, 2026
Case-Based Lessons on Remote Patient Monitoring in Neurology Using Consumer-Grade WearablesPaula Z Epping, Ramona Hagler, Noah M Werner, et al.
Neurological Research and Practice|June 13, 2026
Rethinking EDSS-based ambulation assessment in multiple sclerosis using continuous variable monitoringNoah M Werner, Melanie Schuette, Ramona Hagler, et al.
International Journal of Molecular Sciences|September 28, 2021
Platelet Inhibition by Low-Dose Acetylsalicylic Acid Reduces Neuroinflammation in an Animal Model of Multiple SclerosisAnna Vogelsang, Susann Eichler, Niklas Huntemann, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|June 30, 2025
CD19xCD3 T cell engager blinatumomab effective in refractory generalized myasthenic syndromesTobias Ruck, Niklas Huntemann, Menekse Öztürk, et al.
Journal of Neurology|July 10, 2026
From measurement to biomarker trajectories: platform-agnostic Z score analysis of serum NfL and GFAP in ocrelizumab-treated multiple sclerosisHernan Inojosa, Lars Masanneck, Katja Akgün, et al.
Multiple Sclerosis and Related Disorders|June 14, 2022
Detecting ongoing disease activity in mildly affected multiple sclerosis patients under first-line therapiesLars Masanneck, Leoni Rolfes, Liesa Regner-Nelke, et al.
PLOS Digital Health|July 1, 2026
Exploring attitudes and acceptance of artificial intelligence in multiple sclerosis from the patient perspectiveHernan Inojosa, Lars Masanneck, Isabel Voigt, et al.
Therapeutic Advances in Neurological Disorders|March 26, 2026
Psoriasis under B-cell depleting therapies in multiple sclerosis: a retrospective multicenter analysisPatricia Kirschner, Franz F Konen, Franziska Axhausen, et al.
Annals of Clinical and Translational Neurology|July 10, 2025
Digital Activity Markers in Chronic Inflammatory Demyelinating PolyneuropathyLars Masanneck, Jan Voth, Noëmi Gmahl, et al.
Pageof 4